No Data
Obesity Drugs' Next Wave: These Companies Could Snag 20% of GLP-1 Market, Analysts Say
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Why Viking Therapeutics Is Thriving in the $150 Billion Weight Loss Drug Market
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX)
Viking Therapeutics Could Be a New Winner in the GLP-1 Space